Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.68 |
| ▸ | LPL | P06858 | 10/20 | 0.68 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25491282 | 1.00 | LIPG (0.68) | LIPGLPLPRMT5WDR77DGAT1 | |
| SCHEMBL17343995 | 1.00 | LIPG (0.68) | LIPGLPLPRMT5WDR77DGAT1 | |
| SCHEMBL17343996 | 0.95 | LIPG (0.75) | LIPGLPLDGAT1P4HBKEAP1 | |
| SCHEMBL12791368 | 0.95 | LIPG (0.65) | LIPGLPLPRMT5WDR77DGAT1 | |
| SCHEMBL30009973 | 0.92 | LIPG (0.69) | LIPGLPLDGAT1P4HB | |
| SCHEMBL12791335 | 0.92 | LIPG (0.69) | LIPGLPLDGAT1P4HB | |
| SCHEMBL15856999 | 0.92 | LIPG (0.69) | LIPGLPLDGAT1P4HB | |
| SCHEMBL12126734 | 0.90 | LIPG (0.62) | LIPGLPLPRMT5WDR77DGAT1 | |
| SCHEMBL21636045 | 0.90 | LIPG (0.61) | LIPGLPLPRMT5WDR77DGAT1 | |
| SCHEMBL19106690 | 0.90 | LIPG (0.61) | LIPGLPLPRMT5WDR77DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130304-A1 | COMPOUND, COMPOSITION, ORGANIC OPTOELECTRONIC DIODE, AND DISPLAY DEVICE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-05-06 | — | — | US | disclosed |
| WO-2019146938-A1 | COMPOUND, COMPOSITION, ORGANIC OPTOELECTRONIC DIODE, AND DISPLAY DEVICE | 삼성에스디아이 주식회사 | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130304-A1 | COMPOUND, COMPOSITION, ORGANIC OPTOELECTRONIC DIODE, AND DISPLAY DEVICE | OXER1, OR10J3, OCIAD1 | LIPG 1452/4885LPL 942/4885PRMT5 4430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.